Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Mar;4(3 Suppl):S28-31.
doi: 10.1097/WOX.0b013e3181f8dabb.

Challenges in the management of chronic urticaria

Affiliations

Challenges in the management of chronic urticaria

Todor A Popov. World Allergy Organ J. 2011 Mar.

Abstract

The term "chronic idiopathic urticaria" denotes a spectrum of conditions with different poorly understood pathogenetic mechanisms in which the release of histamine plays a role. Nonsedating second-generation H1 antihistamines are postulated to be the first line of treatment of chronic idiopathic urticaria by national and international guidelines, but as control is not always achievable with the usually recommended doses, first-generation sedating antihistamines like hydroxyzine and diphenhydramine at high daily doses (200 mg) have been proposed as an alternative before resorting to treatment with systemic corticosteroids and other potentially hazardous agents. Our long time experience and recent research give us grounds to believe that increasing the doses of nonsedating H1 antihistamines up to fourfold improves significantly the chances of successful treatment. Our data suggest that the urticaria-associated discomfort is relieved by higher than conventional doses of levocetirizine and desloratadine in about 75% of the patients and that sedation/somnolence does not seem to be a major deterrent. The dose increase also improves the urticaria-specific quality of life. Contrary to the belief that individual patients may benefit from one antihistamine or another, we demonstrate that the drug with better ability to suppress the histamine skin effects in experiments in healthy volunteers (levocetirizine) is also superior in improving the different aspects of control of chronic urticaria (subjective and objective symptoms, quality of life) and that increasing its dose of up to fourfold may even paradoxically reduce the sense of sedation/somnolence in parallel with the relief of urticaria discomfort.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Graphical definition of chronic urticaria.
Figure 2
Figure 2
Results of the study of higher than conventional doses of levocetirizine and desloratadine in difficult-to-treat urticaria (adapted from Staevska et al[25]). The darkened boxes represent the successes at conventional doses for both drugs and the light boxes represent the additional value of dose increase.

References

    1. Greaves M. Chronic urticaria. J Allergy Clin Immunol. 2000;4:664–672. doi: 10.1067/mai.2000.105706. - DOI - PubMed
    1. O'Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997;4:197–201. doi: 10.1111/j.1365-2133.1997.tb14895.x. - DOI - PubMed
    1. Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK. et al.EAACI/GA(2)LEN/EDF/WAO guideline: Definition, classification and diagnosis of urticaria. Allergy. 2009;4:1417–1426. doi: 10.1111/j.1398-9995.2009.02179.x. - DOI - PubMed
    1. Powell RJ, Du Toit GL, Siddique N, Leech SC, Dixon TA. et al.BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy. 2007;4:631–650. doi: 10.1111/j.1365-2222.2007.02678.x. - DOI - PubMed
    1. Konstantinou GN, Asero R, Maurer M, Sabroe RA, Schmid-Grendelmeier P, Grattan CE. EAACI/GA(2)LEN task force consensus report: The autologous serum skin test in urticaria. Allergy. 2009;4:1256–1268. doi: 10.1111/j.1398-9995.2009.02132.x. - DOI - PubMed

LinkOut - more resources